History | Ocrelizumab for treating primary progressive multiple sclerosis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 159 KB)

Published:

12 June 2019

Final draft guidance: 2

Final draft guidance: 2
Committee papers (PDF 937 KB)

Published:

09 May 2019
Final appraisal document (PDF 380 KB)

Published:

09 May 2019

Final appraisal determination

Final appraisal determination
Committee papers (PDF 3.4 MB)

Published:

10 September 2018
Final appraisal determination document (PDF 330 KB)

Published:

10 September 2018
Public committee slides (PDF 734 KB)

Published:

10 September 2018

Draft guidance

Draft guidance
Public committee slides (PDF 1.01 MB)

Published:

29 June 2018
Committee papers (PDF 22.13 MB)

Published:

29 June 2018
Appraisal consultation document (PDF 336 KB)

Published:

29 June 2018

Invitation to participate

Final scope (PDF 95 KB)

Published:

03 October 2017
Final matrix (PDF 251 KB)

Published:

03 October 2017
Equality impact assessment (Scoping) (PDF 175 KB)

Published:

26 September 2017
NICE's response to comments on the draft scope and provisional matrix (PDF 300 KB)

Published:

03 October 2018

Draft scope documents

Draft scope (pre-referral) (PDF 113 KB)

Published:

01 February 2017
Provisional matrix (pre-referral) (PDF 36 KB)

Published:

01 February 2017